Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Partners unveil Erbitux deal for Japan

ImClone (IMCL), Bristol-Myers (BMY) and Merck KGaA (FSE:MRK) agreed to co-develop and co-commercialize Erbitux

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE